Upstream’s key claims considered novel, inventive and have industrial applicability
A patent report received by Upstream today from the World Intellectual Property Organization (WIPO) has noted that its key claims for its Maker C patent are novel, inventive and have industrial applicability.
This report is very encouraging for the future of cardiac healthcare as it paves the way to continue the development of biomarkers which will support the rapid diagnosis of the risk of a patient having an imminent heart attack.
Detecting at-risk heart attack patients, a step closer with $2m investment
Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.
Upstream commences testing Marker C on the APACE cohort
The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.